Bristol-Myers Squibb, Bluebird Bio Release Results of KarMMa Phase 2 Study
December 06 2019 - 5:30PM
Dow Jones News
By Stephen Nakrosis
Bristol-Myers Squibb Co. (BMY) and bluebird bio Inc. (BLUE) said
results from a Phase 2 study of their idecabtagene vicleucel
treatment for certain myeloma patients met its primary endpoint and
key secondary endpoint.
Idecabtagene vicleucel, or ide-cel, is an investigational
treatment for certain patients with relapsed and refractory
multiple myeloma, the companies said.
The KarMMa Phase 2 study "met its primary endpoint and key
secondary endpoint, demonstrating deep and durable responses in a
heavily pre-treated multiple myeloma patient population," the
companies said.
The companies said they are "are actively preparing for
submission of these data to health authorities for proposed initial
registration of ide-cel as a first-in-class BCMA-targeted CAR T
cell therapy."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 06, 2019 17:15 ET (22:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Aug 2024 to Sep 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Sep 2023 to Sep 2024